Carlyle finds its first big biotech bet after teaming with Abingworth
Carlyle Group and Abingworth are putting their combined powers to use, extending a custom financing deal to an Australian public company that’s in the middle of Phase III studies in wet age-related macular degeneration.
Money — $170 million of it in total — is just the first part. Through their new development crew at Launch Therapeutics, the investors are also to lend clinical, regulatory and commercial expertise to Opthea as it tries to usher its OPT-302 to the market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.